Texas Medical Center (TMC) has partnered with Japan-based Mitsui Fudosan Co., Ltd. and the National Cancer Center to launch the strategic alliance TMC Japan BioBridge and JACT (Japan Accelerator Cancer Therapy Device). Announced. It aims to advance cancer treatment by connecting Japanese innovators with Texas Medical Center experts and providing a path to expanding the U.S. market.
“The launch of the TMC Japan BioBridge is an important step forward in bringing together two global leaders in healthcare innovation,” said William F. McKeon, President and CEO of TMC. “Japan’s leadership has demonstrated a great commitment to advancing medical and life science technologies, and through this partnership, we are opening the door Japanese researchers and innovators need to access the U.S. market and collaborate with the TMC ecosystem. Together, we aim to accelerate important advances that make a difference for patients around the world.”
In 2016, TMC launched the organization’s first BioBridge, designed to provide a focused and strategic pathway for international healthcare companies preparing to expand into the U.S. market. JACT provides this structured process to Japanese oncology companies from the initial program period, during which participants gain insight into the U.S. healthcare system. From there, these companies will meet with decision makers from pharmaceutical companies, hospital systems, and investors to receive expert feedback on preparing for U.S. regulatory approval.
“TMC Japan BioBridge provides an exciting and focused opportunity for Japanese companies to understand and address the complexities of U.S. healthcare,” said Tsuyoshi Kozane, Director of Kashiwanoha City Planning and Development Department, Mitsui Fudosan Co., Ltd. says Mr. He will play a leading role in this effort to foster innovation and collaboration between Japan and the United States in cancer treatment and life sciences. ”
JACT will focus on three key areas throughout the program: 1) Milestone development and financial planning. Participants will receive guidance on developing product milestones and managing financial requirements to support their US market ambitions. 2) Clinical and regulatory expertise will be provided to participants. 3) access to key US-based opinion leaders and mentors in clinical trial design, manufacturing, and regulatory strategies for streamlined US entry; and 3) access to key US-based opinion leaders and mentors in clinical trial design, manufacturing, and regulatory strategies for streamlined US entry; Gain strategic partnerships and market insights based in Health management advisors support successful commercialization.
A Texas Medical Center delegation recently traveled to Tokyo, Japan, for a week of discussions focused on the development of Houston’s innovation ecosystem, Japan’s bioindustry policy, and plans to support life science ventures. Participating organizations in Japan include AMED (Japan Agency for Medical Research and Development), NCC (National Cancer Center), MHLW (Ministry of Health, Labor and Welfare), JBA (Japan Bioindustry Association), and JETRO (Japan External Trade Organization). . others.
“This TMC Japan BioBridge and JACT program will help accelerate the development of startups seeking to commercialize innovative Japanese medical technologies in the United States. )” Center Seed Acceleration Program: NCC SAP) This will lead to further collaboration in various fields with TMC, NCC, and other Japanese institutions,” said Hitoshi Nakagama, Director of the National Cancer Center.
The TMC Japan BioBridge Memorandum of Understanding (MoU) was signed by William F. McKeon, President and CEO of Texas Medical Center, on November 5, 2024 in Tokyo, Japan. Mitsui Fudosan Co., Ltd. General Manager Takeshi Kozane; National Cancer Center Chairman Hitoshi Nakagama.
This is the sixth international strategic alliance, including alliances with the Netherlands, Australia, the United Kingdom, Denmark, and Ireland. Since 2016, TMC’s BioBridges specializes in digital health and medical devices across a variety of critical areas including neurology, oncology, patient engagement, surgery, orthopedics, cardiovascular health, transplantation, intensive care, and ophthalmology. We have accepted 88 startup companies. JACT introduces collaboration and knowledge opportunities to further expand TMC’s global footprint and commitment to medical innovation.
MB Bureau
